Archivel Farma

Archivel Farma is a dual-focus biotechnology company with a proprietary immunotherapeutic vaccine program for tuberculosis (RUTI®) and a growing CDMO services business. Its core assets include GMP-certified manufacturing facilities with Biosafety Level 3 (BSL-3) containment, enabling the production of sterile, freeze-dried biological products for itself and client partners. The company is advancing RUTI® into clinical studies for tuberculosis and exploring its application in oncology, such as bladder cancer, while simultaneously expanding its service offerings following a recent GMP certification renewal.

GMP/BSL-3 manufacturing platform for sterile, freeze-dried biologicals; proprietary fragmented liposomal vaccine technology for immunotherapy (RUTI®).

In TB therapeutics, RUTI® competes with other novel vaccines and host-directed therapies in development by larger entities like GSK and various biotechs. In bladder cancer, it enters a competitive immuno-oncology field. As a CDMO, it competes in a niche segment with other specialized manufacturers offering high-containment bioprocessing.